普拉克索联合多巴丝肼片治疗帕金森病的疗效及CRP、TNF-α水平影响分析

Analysis of the Curative Effect of Pramipexole Combined with Dopasalzine Tablets in the Treatment of Parkinson's Disease and the Influence of CRP and TNF-αLevels

目的探讨普拉克索联合多巴丝肼片治疗帕金森病的疗效及对C反应蛋白(CRP)与肿瘤坏死因子-α(TNF-α)水平影响。方法选择2019年4月-2020年3月该院收治的帕金森患者90例,以随机数表法将其分为两组。对照组45例应用多巴丝肼片治疗,研究组45例在此基础上应用普拉克索治疗。对比两组临床疗效,治疗前后帕金森病统一评分量表(UPDRS)评分,治疗前后CRP、TNF-α水平,以及不良反应。结果两组总有效率对比中,研究组(95.56%)较对照组(80.00%)更高,差异有统计学意义(χ^(2)=5.075,P<0.05);治疗后研究组UPDRS量表中日常生活活动能力评分(21.6±2.8)分、运动功能评分(24.6±2.8)分、情绪和精神行为评分(6.5±0.6)分较对照组(30.4±2.4)分、(32.5±2.0)分、(9.2±0.8)分更低,差异有统计学意义(t=16.007,15.401,18.112,P<0.001)。治疗后研究组CRP(3.5±0.8)mg/L与TNF-α(4.8±1.2)ng/L较对照组(4.5±1.2)mg/L、(6.9±1.6)ng/L更低,差异有统计学意义(t=4.651,7.044,P<0.001)。两组不良反应对比差异无统计学意义(χ^(2)=0.137,P>0.05)。结论普拉克索联合多巴丝肼片治疗帕金森病的效果确切,且可以改善血清CRP、TNF-α水平,适于临床应用。

Objective To explore the efficacy of pramipexole combined with dopasalzine tablets in the treatment of Parkinson's disease and the influence of C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)levels.Methods A total of 90 Parkinson's patients admitted to the hospital from April 2019 to March 2020 were selected and divided into two groups by random number table.45 cases in the control group were treated with dopasrazide tablets,and 45 cases in the study group were treated with pramipexole on this basis.The clinical effects of the two groups were compared,the Parkinson’s Disease Unified Score Scale(UPDRS)before and after treatment,CRP,TNF-αlevels before and after treatment,and adverse reactions.Results In the comparison of the total effective rate between the two groups,the study group was 95.56%higher than the control group 80.00%,the difference was statistically significant(χ^(2)=5.075,P<0.05).After treatment,the study group’s UPDRS scores on activities of daily living(21.6±2.8)points,motor function scores(24.6±2.8)points,emotional and mental behavior scores(6.5±0.6)points were compared with those in the control group(30.4±2.4)points,(32.5±2.0)points,(9.2±0.8)points were lower,the difference was statistically significant(t=16.007,15.401,18.112,P<0.001).After treatment,CRP(3.5±0.8)mg/L and TNF-α(4.8±1.2)ng/L in the study group were lower than those in the control group(4.5±1.2)mg/L and(6.9±1.6)ng/L,the difference was statistically significant(t=4.651,7.044,P<0.001).There was no statistically significant difference in adverse reactions between the two groups(χ^(2)=0.137,P>0.05).Conclusion Pramipexole combined with dopasserzide tablets has a definite effect in the treatment of Parkinson's disease,and can improve serum CRP and TNF-αlevels,which is suitable for clinical application.